These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. Taylor JW; Parikh M; Phillips JJ; James CD; Molinaro AM; Butowski NA; Clarke JL; Oberheim-Bush NA; Chang SM; Berger MS; Prados M J Neurooncol; 2018 Nov; 140(2):477-483. PubMed ID: 30151703 [TBL] [Abstract][Full Text] [Related]
14. Expression pattern and prognostic significance of myosin light chain 9 (MYL9): a novel biomarker in glioblastoma. Kruthika BS; Sugur H; Nandaki K; Arimappamagan A; Paturu K; Santosh V J Clin Pathol; 2019 Oct; 72(10):677-681. PubMed ID: 31270134 [TBL] [Abstract][Full Text] [Related]
15. The challenges associated with molecular targeted therapies for glioblastoma. Jue TR; McDonald KL J Neurooncol; 2016 May; 127(3):427-34. PubMed ID: 26900075 [TBL] [Abstract][Full Text] [Related]
16. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. Dehdashti AR; Hegi ME; Regli L; Pica A; Stupp R Neurosurg Focus; 2006 Apr; 20(4):E6. PubMed ID: 16709037 [TBL] [Abstract][Full Text] [Related]
17. Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial. Olafson LR; Siddell AH; Field KM; Byrnes M; Rapkins RW; Ng B; Nixdorf S; Barnes EH; Johns TG; Yip S; Simes J; Nowak AK; Rosenthal MA; McDonald KL J Clin Neurosci; 2019 Dec; 70():157-163. PubMed ID: 31582283 [TBL] [Abstract][Full Text] [Related]